It is quite the curiosity that these mostly vancomycin-like antibiotics have any effect at all on viruses, much less a critically important one
We previously reported that teicoplanin, a glycopeptide antibiotic which has routinely been used in the clinic to treat bacterial infection with low toxicity, significantly inhibits the invasion of cells by Ebola virus, SARS-CoV and MERS-CoV, via specifically inhibiting the activity of cathepsin L.
It’s interesting that the first coronavirus patient in Washington state was put on a vancomycin drip when he developed pneumonia.
Unfortunately he was worse the next day.
So vanc itself doesn’t seem to do anything. At least if it’s started after major symptoms have appeared.
* * *